The USPTO published notice of trademark application TM99431686 for HERLYSTIC, covering pharmaceutical preparations targeting HER2 protein for cancer treatment, immunotherapy pharmaceutical preparations, and vaccine preparations targeting HER2 protein for cancer treatment. The application was filed on October 7, 2025, under Intent-to-Use basis.\n\nPharmaceutical companies developing HER2-targeted therapies should review this application to assess potential conflicts with their existing or planned product branding. Trademark applications in Class 005 may affect future product naming decisions in the oncology space. No immediate compliance action is required; this is an informational filing.